CH 799

Drug Profile

CH 799

Latest Information Update: 18 May 1998

Price : $50

At a glance

  • Originator Celltech Group
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Purine nucleoside phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Irritable bowel syndrome; Osteoarthritis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 18 May 1998 Discontinued-Preclinical for Rheumatoid arthritis in United Kingdom (PO)
  • 18 May 1998 Discontinued-Preclinical for Osteoarthritis in United Kingdom (PO)
  • 18 May 1998 Discontinued-Preclinical for Irritable bowel syndrome in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top